Avai Bio Q1 FY27 net loss widens 13% to $552,041; revenue remains no revenue

• Avai Bio posted a net loss of $552,041 for the quarter ended June 30, 2026, widening 13%.
• Operating loss narrowed 13.9% to $419,783; operating expenses fell to $419,783 on lower marketing and professional fees.
• Other expenses swung to $132,258 from none, driven by interest and discount on convertible notes, loan interest, and a loss on disposal.
• Cash rose to $83,586; working capital deficit widened to $3.86 million.
• Net cash used in operations increased to $414,258; financing cash inflows climbed to $533,299.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avai Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001740797-26-000021), on August 13, 2026, and is solely responsible for the information contained therein.